Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Public ClinicalTrials.gov record NCT05857969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Advancing Personalized Treatment in Pediatric Oncology Through Functional Precision Medicine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.
Study identification
- NCT ID
- NCT05857969
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 65 participants
Conditions and interventions
Conditions
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Large Cell Lymphoma
- Refractory Childhood Acute Lymphoblastic Leukemia
- Refractory Childhood Hodgkin Lymphoma
- Refractory Childhood Malignant Germ Cell Neoplasm
- Recurrent Childhood Brain Tumor
- Recurrent Childhood Brainstem Glioma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Childhood Ependymoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Gliosarcoma
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Childhood Malignant Solid Neoplasm
- Recurrent Childhood Malignant Solid Neoplasm
- Recurrent Childhood Malignant Neoplasm
- Refractory Childhood Malignant Neoplasm
Eligibility (public fields only)
- Age range
- 1 Day to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2023
- Primary completion
- Feb 21, 2028
- Completion
- Dec 30, 2028
- Last update posted
- Aug 25, 2026
2023 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nicklaus Children's Hospital | Miami | Florida | 33155 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05857969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05857969 live on ClinicalTrials.gov.